Gene Therapy with HSV1-sr39TK/GCV Exhibits a Stronger Therapeutic Efficacy Than HSV1-TK/GCV in Rat C6 Glioma Cells
Figure 3
Growth inhibition in cultured C6-TK and C6-sr39TK cells 72 hours after ganciclovir (GCV) administration. Cell survival rate (SR) was measured by MTT assay, which showed SR in C6-TK and, especially, the C6-sr39TK group was significantly decreased in a dose-dependent manner as compared with that of the control (* versus C6 group; ** versus C6 group; ## versus C6-TK group).